<DOC>
	<DOCNO>NCT00244023</DOCNO>
	<brief_summary>30 50 % patient present Erectile Dysfunction ( ED ) respond PDE V Inhibitor therapy , presently consider first choice treatment ED patient . Recent report state high prevalence low serum testosterone level non responder , improvement response combine testosterone therapy PDE V Inhibitor . This suggest may minimum threshold level blood testosterone full effectiveness PDE V Inhibitor therapy . Two double blind , placebo control study add support hypothesis one involve 20 patient benefit combine testosterone transient . This multi-centric study , double blind placebo control randomized concern testosterone administration , aim objectively assess efficacy co-administering testosterone PDE 5 inhibitor Tadalafil improve erectile function large group ED patient non-responders PDE V inhibitor alone . Patients screen ensure inclusion exclusion criterion completion , include serum testosterone level &lt; 4 ng/ml total testosterone &lt; 1 ng/ ml bioavailable testosterone . They enter four week run-in period meanwhile receive Tadalafil 10 mg , daily , order confirm non responsiveness PDE V inhibitor eligibility enter treatment phase base IIEF score , SEP diaries Global Assessment Question ( GAQ ) . The patient still non responder 4 week Tadalafil 10 mg daily enter 12 week treatment phase include visit week 4 , 8 , 12 16 . Treatment procedure include : 1. continuation Tadalafil 10 mg dose daily follow routine assessment use SEP diary , IIEF scoring , GAQ Aging Male Symptoms scale administer study visit . Safety assessment perform addition last visit ( physical examination include DRE , PSA BCC ) . 2 . Randomization 2 parallel arm ( Placebo gel + Tadalafil 10 mg daily , Testosterone gel 50 mg + Tadalafil 10 mg daily ) . If indicate accord suboptimal clinical response patient , dose study medication increase 8 12 week visit 100mg testosterone 2 sachet placebo gel . Up 430 patient screen order 172 enrol double blind treatment phase .</brief_summary>
	<brief_title>Co-Administering Testosterone With PDE5 Inhibitors ED Patients Non Responders PDE5 Inhibitors Alone</brief_title>
	<detailed_description>Design Methodology : This multicentre , randomise , double-blind , placebo-controlled study effect co-administering testosterone PDE 5 inhibitor tadalafil ED patient respond PDE 5 inhibitor alone . The patient randomise two parallel group : Control group ( tadalafil plus placebo ) Test group ( tadalafil plus testosterone ) . The study last maximum 16 week patient divide two part : - Run-in phase : four week period visit 1 ( V1 ) V2 patient receive dose 10 mg tadalafil per day . Non-response tadalafil assess SEP diary , IIEF questionnaire GAQ . Patients attempt intercourse least four time phase . Non-responders randomise V2 . - Treatment phase : 12 week period day V2 V5 visit week 8 , 12 16 . The patient response assess SEP diary , IIEF AMS questionnaires GAQ visit . Patients apply testosterone placebo gel skin day , preferably morning . There option increase dose testosterone placebo V3 V4 patient suboptimal clinical response ( patient felt insufficiently improve achieve score low 5 question 3 4 IIEF ) . Test product . The product give study license name Cialis ( tadalafil ) Androgel Testogel ( testosterone gel ) . All patient treat 10 mg tadalafil tablet daily four week run-in phase , randomise , follow 12 week treatment phase . Patients Test group treat 5 g sachet testosterone gel ( 50 mg testosterone ) daily 12 week treatment phase , option increase two 5 g sachet ( 100 mg testosterone ) per day V3 V4 patient suboptimal clinical response ( patient felt insufficiently improve achieve score low 5 question 3 4 IIEF questionnaire ) . Patients Control group receive 5 g sachet placebo gel daily 12 week treatment phase , option increase two 5 g sachet per day V3 V4 . Statistical methods 1 . Descriptive statistic : 1 . Categorical variable summarise use classical frequency statistic : number non-missing observation ( N ) percentages ( % ) category . Percentages calculate within treatment group number non-missing observation display use one decimal . 2 . Continuous variable summarise use standard quantitative statistic . number non-missing observation ( N ) , mean , standard deviation ( SD ) , median range ( minimum maximum observe value ) . The number miss observation ( N miss ) also specify . The 95 % confidence interval ( CI ) display relevant . 2 . Inferential analysis : Comparisons treatment group two-sided . The significance level set 0.050 . All p-values round three decimal places.Main inferential analysis use one follow test : 1 . Chi two-Test Fisher 's exact Test comparing distribution categorical variable level one factor ( e.g . treatment arm ) , reference theoretical distribution . When least one theoretical frequency less 5 , Fisher 's exact test use place Chi two-Test 2 . Analysis variance ( ANOVA ) : compare mean value continuous quantitative variable level categorical factor ( e.g . treatment group , centre ) 3 . Analysis covariance ( ANCOVA ) ANOVA adjust treatment group centre effect baseline value covariate : The primary efficacy criterion analyse ANCOVA , include covariate 'baseline value primary criterion ' factor 'treatment group ' . The ANCOVA estimate difference two treatment well two-sided 95 % CI . Summary conclusion Efficacy result : Of 173 patient include study , 35 prematurely withdrawn . Therefore 138 patient complete study . The ITT population consist 167 patient PP population 120 ; 47 patient ITT population exclude major protocol deviation . No statistically significant difference find testosterone placebo group concern primary criterion either ITT PP population . The EFD score IIEF questionnaire increase baseline ( V2 efficacy result ) endpoint ( V5 withdrawal visit ) group , indicate overall improvement erectile function study . Apart hormone level , statistically significant difference secondary criterion either ITT PP population . As expect , certain hormone significant difference two group ( total testosterone ( TT ) , bioavailable testosterone ( BT ) , Dihydrotestosterone ( DHT ) , oestradiol , luteinizing hormone ( LH ) , follicle stimulate hormone ( FSH ) , calculate FT ( cFT ) calculate BT ( cBT ) ) . Significant difference also find hormone treatment responder . There statistically significant difference additional analysis ; percentage successful sexual intercourse attempt amongst treatment responder similar group . At V2 , run-in phase four week tadalafil treatment alone , responder rate 17.0 % rate patient score &gt; 26 EFD IIEF i.e . consider longer ED , 14.8 % . For domain IIEF , score high V2 V1 , indicate increase erectile function run-in phase . Almost half select patient ( 44.8 % ) think tadalafil treatment improved erection . However , result exploratory analysis may bias perform Selected population ( responded IIEF V1 V2 ) Randomised population . Additional exploratory analysis perform determine testosterone threshold possible improvement would obtain testosterone gel . The result analyse found statistically significant difference two group , favour Test group , ITT patient TT level 3 ng/ml less baseline . The result include significantly high increase primary criterion ( EFD score ) V4 ( p=0.027 ) , 8 week testosterone gel , significantly great improvement various secondary criterion . For IIEF questionnaire : significant improvement show score Orgasmic Function Domain V4 ( p=0.028 ) , Intercourse Satisfaction Domain V4 ( p=0.005 ) , Overall Satisfaction Domain endpoint ( p=0.046 ) total IIEF score V4 ( p=0.008 ) . For SEP diary significantly high increase show rate attempt intercourse result vaginal penetration ( SEP 2 ) V4 ( p=0.033 ) , rate totally successful intercourse ( SEP 3 ) V4 ( p=0.038 ) endpoint ( p=0.006 ) . These result suggest testosterone gel significantly improve erectile function compare placebo gel ED patient non-responders PDE5 inhibitor baseline testosterone level 3 ng/ml less , effect discernible second month administration ( assessment do V4 ) . Safety result Overall , 61 173 Safety population patient ( 35.3 % ) experience least one AE study ( 111 AEs report total ) AEs report Control group Test group . In Safety population , 32 pre-treatment AEs record 23 patient ( 13.3 % ) significant difference group . During study , total 79 emergent AEs record 53 patient ( 30.6 % ) , 34 AEs 22 Test group patient 45 AEs 31 Control group patient . All AEs mild moderate intensity , except four AEs consider severe , report Test group ( pneumopathy , arrythmia , bowel obstruction exacerbation back pain ) . The latter severe AE relate one study product . Five emergent AEs consider serious three Test group patient ( coronary stenosis diabetes , pneumopathy arrhythmia , bowel obstruction ) . These SAEs unrelated study product . The patient bowel obstruction withdrawn study V4 . A total 11 patient ( four Test group -diabetes impaired corticotherapy , itching , bowel obstruction , nausea- seven Control group ) withdrawn study due AE . Conclusions In conclusion , study , testosterone gel improve efficacy tadalafil population ED patient low low-to-normal testosterone level ( TT &lt; 4 ng/ml BT &lt; 1 ng/ml ) non-responders tadalafil 10 mg once-a-day alone . However additional exploratory analysis find significant improvement tadalafil plus testosterone gel compare tadalafil plus placebo gel subgroup ITT population restrict patient serum TT level &lt; 3 ng/ml baseline . These result agree scientific literature , place threshold level man may consider hypogonadal ( testosterone deficient ) 3 ng/ml ( inclusion criterion 4 ng/ml ) .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>1 . ED complaint ongoing 3 month ; 2 . Age comprise 45 80 year old ; 3 . Had stable heterosexual relationship 3 month anticipate partner study 4 . Has respond adequately high available dosage Tadalafil PDE5 inhibitor ( 20 mg Tadalafil Vardenafil , 100 mg Sildenafil ) take least 4 separate occasion , define : score 2,3 4 Question 3 IIEF AND score 2 3 Question 4 IIEF ; measure prior Visit 1 5 . Low lowtonormal serum testosterone level ( either total bioavailable testosterone level ) respect range men age 50 y.o . ( TT &lt; 4 ng/ml and/or BT &lt; 1 ng/ml ) accord first assay do prior Visit 1 confirmation second assay central laboratory Biolille blood sample Visit 1 6 . Agrees make least 4 attempt sexual intercourse 4 separate day 4 week runin period daily Tadalafil 10 mg 7 . At least 50 % attempts period must unsuccessful accord answer `` No '' one question 1 ( `` able achieve least erection ( enlargement penis ) ? `` ) , 2 ( `` able insert penis partner 's vagina ? '' ) 3 ( `` erection last long enough successful intercourse ? '' ) . 8 . At end run phase Tadalafil 10 mg daily , patient provide : score 2 , 3 4 Question n°3 IIEF AND score 2 , 3 Question n°4 IIEF 9 . Agrees use ED drug nondrug ( device ) treatment full course study ; 10 . Provides sign informed consent . 1 . Impotence cause primary sexual disorder ( e.g . premature ejaculation ) ; 2 . History penile implant significant penile deformity ; 3 . Body mass index &gt; 35kg/m2 ; 4 . Diabetes mellitus uncontrolled ( HbA1c level &gt; 10 % ) . HbA1c check screen diabetic patient suspect ; 5 . Uncontrolled thyroid disorder ; 6 . Known hyperprolactinemia ( serum prolactin &gt; 30ng/ml local laboratory ) ; 7 . Organic hypothalamicpituitary pathology ; 8 . History alcohol , drug substance abuse within 6 month Visit 1 ; 9 . Renal insufficiency define receive renal dialysis , creatinine clearance &lt; 30 ml/mn , serum creatinine &gt; 30 mg/ml ; 10 . Severe hepatic impairment , Child Pugh class C , elevation AST and/or ALT &gt; 3 x ULN ; 11 . Systolic Blood Pressure &gt; 170 &lt; 90 mm Hg diastolic blood pressure &gt; 110 &lt; 50 mm Hg screening ; 12 . Cardiac disease contraindicate sexual activity ; 13 . Unstable angina within 6 month Visit 1 ; 14 . Angina sexual intercourse within 6 month Visit 1 ; 15 . Myocardial Infarction within 90 day Visit 1 ; 16 . Coronary artery bypass graft surgery percutaneous coronary intervention ( angioplasty stent insert ) within 90 day Visit 1 ; 17 . Severe cardiac rhythm disturbance e.g . supraventricular arrhythmia ventricular response &gt; 100 bpm . rest despite medical device therapy , history refractory spontaneous induce sustained ventricular tachycardia ( heart rate &gt; 100 bpm . &gt; 30 sec ) fibrillation , automatic internal cardioverterdefibrillator , history sudden cardiac arrest ) within 6 month Visit 1 ; 18 . Known new significant conduction defect evaluate regard significance within 90 day prior Visit 1 ; 19 . Congestive heart failure ( NYHA Class II ) within 6 month Visit 1 ; 20 . History stroke within 6 last month ; 21 . Epilepsy adequately control treatment ; 22 . Polycythemia hematocrit &gt; 52 % study entry ( i.e . screen visit/visit 1 ) ; 23 . Suspicion current , past history prostate breast cancer ; 24 . Severe symptomatic Benign Prostate Hyperplasia ; 25 . PSA value exceed age specific reference range publish Richardson Oesterling , Urol Clin North Am , 1997 , 24 : 339351 26 . Diagnosed sleep apnea ; 27 . Extensive skin abnormality could affect absorption gel ; 28 . Any clinically significant chronic disease might , opinion investigator , compromise patient 's safety , interfere evaluation , preclude completion trial ( e.g . hemochromatosis , chronic lung disease , chronic malabsorption disease ) ; 29 . History HIV infection ; 30 . Severe psychiatric disease ; 31 . Illiteracy , lack fluency language use write protocol questionnaire , unwillingness , medical , psychiatric condition compromise patient 's ability understand patient information , give informed consent , understand complete diary questionnaire otherwise comply trial protocol , complete study ; 32 . Known hypersensitivity Cialis ( Tadalafil ) ; 33 . Hypersensitivity active substance excipients Androgel®/ Testogel® ; 34 . Use androgen therapy anabolic steroid within 6 month entry study ( i.e . screen visit/visit 1 ) ; 35 . Concurrent use follow medication : androgen include dehydroepiandrosterone ( DHEA ) anabolic steroid , antiandrogens , estrogen , corticotrophin ( ACTH ) , oxyphenylbutazone , clomipramine , Serotonin Reuptake Inhibitors , long shortacting nitrate , NO donor , potent cytochrome P3A4 inhibitor ( e.g . ketoconazole , itraconazole , ritonavir , saquinavir , macrolides like erythromycin ) , cancer chemotherapy ; 36 . Patients unwilling cease use vacuum device , intracavernosal injection , Viagra , therapy ED ; 37 . Patients seek conception treatment infertility ; 38 . Concurrent participation another clinical trial within 1 month entry study ( i.e . screen visit/visit 1 ) throughout duration study ; 39 . Previous randomization study . 40 . History temporary permanent partial complete blindness</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Testosterone Therapy</keyword>
	<keyword>PDE V Inhibitor</keyword>
	<keyword>Tadalafil</keyword>
</DOC>